Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 known ✓ | P25103 | 2/20 | 0.33 |
| ▸ | SNCA | P37840 | 2/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 3/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL5972756 | 0.96 | SNCA (0.50) | SNCAHIF1AAPPCYP1A2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL19994592 | 0.85 | SNCA (0.44) | SNCAHIF1AIDO1SLC1A1PPARG | |
| Bromide SCHEMBL22091635 | 0.84 | SNCA (0.44) | SNCAHIF1AAPPCYP1A2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL376693 | 0.82 | SNCA (0.58) | SNCAHIF1AALDH1A1IDO1PPARG | |
| Bromide SCHEMBL1352977 | 0.81 | SNCA (0.47) | SNCAHIF1AIDO1SLC1A1PPARG | |
| SCHEMBL29751859 | 0.79 | SNCA (0.60) | SNCAHIF1AALDH1A1IDO1PPARG | |
| SCHEMBL29392833 | 0.79 | SNCA (0.60) | SNCAHIF1AALDH1A1IDO1PPARG | |
| Bromide SCHEMBL6457063 | 0.78 | SNCA (0.49) | SNCAHIF1AAPPCYP1A2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL2446696 | 0.78 | SNCA (0.69) | SNCAHIF1AAPPCYP1A2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL494 | 0.78 | SNCA (0.63) | SNCAHIF1AAPPCYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9765065-B2 | Therapeutic substituted cyclopentanes | ALLERGAN, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170144999-A1 | THERAPEUTIC SUBSTITUTED CYCLOPENTANES | ALLERGAN, INC. | 2017-05-25 | — | — | US | disclosed |
| US-9591935-B2 | Therapeutic substituted cyclopentanes | ALLERGEN, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| CN-101795692-B | Therapeutic substituted cyclopentanes for reducing intraocular pressure | OLD DAVID W | 2013-06-12 | — | — | CN | disclosed |
| EP-2170345-B1 | THERAPEUTIC SUBSTITUTED CYCLOPENTANES FOR REDUCING INTRAOCULAR PRESSURE | ALLERGAN INC (US) | 2013-03-06 | — | — | EP | disclosed |
| US-20110062165-A1 | BALANCED INDIVIDUAL DINING PLATE | ALLERGAN INC | 2011-03-17 | — | — | US | disclosed |
| EP-2170345-A1 | THERAPEUTIC SUBSTITUTED CYCLOPENTANES FOR REDUCING INTRAOCULAR PRESSURE | Allergan, Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009006370-A1 | THERAPEUTIC SUBSTITUTED CYCLOPENTANES FOR REDUCING INTRAOCULAR PRESSURE | ALLERGAN, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170144999-A1 | THERAPEUTIC SUBSTITUTED CYCLOPENTANES | CYP11B2, CYP11B1, HMGCR | TACR1 567/4885SNCA 2243/4885HIF1A 1015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.